Regulatory mechanisms of PD-L1 expression in cancer cells

Comprehensive molecular characterization of gastric adenocarcinoma

The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498 · see citing works

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,684 · see citing works

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · see citing works

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation

Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · see citing works

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942 · see citing works

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

Chen, L., & Han, X. N. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,433 · see citing works

MYC regulates the antitumor immune response through CD47 and PD-L1

Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403 · see citing works

FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma

Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365 · see citing works

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,341 · see citing works

Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations

Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337 · see citing works

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

Green, M. R., Monti, S., Rodig, S. J., Juszczyński, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D. S., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,307 · see citing works

Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy

Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300 · see citing works

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,237 · see citing works

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147 · see citing works

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Li, C., Lim, S., Xia, W., Lee, H., Chan, L.-C., Kuo, C., Khoo, K., Chang, S.-S., Cha, J., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,100 · see citing works

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013 · see citing works

PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression

Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981 · see citing works

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Choueiri, T. K., Escudier, B. J., Powles, T. B., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F. N., Roth, B. J., Peltola, K. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 964 · see citing works

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

Burr, M. L., Sparbier, C. E., Chan, Y.-C., Williamson, J. C., Woods, K., Beavis, P. A., Lam, E. Y. N., Henderson, M. A., Bell, C. C., Stolzenburg, S., et al. (2017) · Nature · doi:10.1038/nature23643 · Cited by 946 · see citing works

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 892 · see citing works

Deubiquitination and Stabilization of PD-L1 by CSN5

Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793 · see citing works

Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785 · see citing works

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M. E., Wang, H. Y., Wysocka, M., Cheng, M. M., Ruggeri, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 731 · see citing works

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

Mezzadra, R., Sun, C., Jae, L. T., Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M. E. W., Slagter, M., Rozeman, E. A., Hofland, I., et al. (2017) · Nature · doi:10.1038/nature23669 · Cited by 697 · see citing works

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

Green, M. R., Rodig, S. J., Juszczyński, P., Ouyang, J., Sinha, P., O’Donnell, E. A., Neuberg, D. S., & Shipp, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1942 · Cited by 687 · see citing works

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653 · see citing works

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

Kataoka, K., Shiraishi, Y., Takeda, Y., Sakata, S., Matsumoto, M., Nagano, S., Maeda, T., Nagata, Y., Kitanaka, A., Mizuno, S., et al. (2016) · Nature · doi:10.1038/nature18294 · Cited by 647 · see citing works

Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway

Liu, J., Hamrouni, A., Wołowiec, D., Coiteux, V., Kuliczkowski, K., Hétuin, D., Saudemont, A., & Quesnel, B. (2007) · Blood · doi:10.1182/blood-2006-10-051482 · Cited by 580 · see citing works

Ubiquitin: Same Molecule, Different Degradation Pathways

Clague, M. J., & Urbé, S. (2010) · Cell · doi:10.1016/j.cell.2010.11.012 · Cited by 535 · see citing works

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525 · see citing works

MYC: Connecting selective transcriptional control to global RNA production

Kress, T. R., Sabò, A., & Amati, B. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3984 · Cited by 521 · see citing works

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

Woods, D. M., Sodré, A. L., Villagra, A., Sarnaik, A., Sotomayor, E. M., & Weber, J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0077-t · Cited by 454 · see citing works

Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274)

Lee, S. J., Jang, B., Lee, S.-W., Yang, Y., Suh, S., Park, Y.-M., Oh, S., Shin, J., Yao, S., Chen, L., et al. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.093 · Cited by 446 · see citing works

Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

Ota, K., Azuma, K., Kawahara, A., Hattori, S., Iwama, E., Tanizaki, J., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0016 · Cited by 438 · see citing works

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression

Zhu, H., Bengsch, F., Svoronos, N., Rutkowski, M. R., Bitler, B. G., Allegrezza, M. J., Yokoyama, Y., Kossenkov, A. V., Bradner, J. E., Conejo-Garcia, J. R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.032 · Cited by 435 · see citing works

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

Berthon, C., Raffoux, E., Thomas, X., Vey, N., Gomez‐Roca, C., Yee, K. W. L., Taussig, D. C., Rezaï, K., Roumier, C., Herait, P., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00247-1 · Cited by 423 · see citing works

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Amorim, S., Stathis, A., Gleeson, M., Iyengar, S., Magarotto, V., Leleu, X. P., Morschhauser, F., Karlin, L., Broussais, F., Rezaï, K., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00021-1 · Cited by 422 · see citing works

Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression

Xu, C., Brainson, C. F., Koyama, S., Wu, H., Zhao, Y., Chen, Z., Herter-Sprie, G. S., Akbay, E. A., Tchaicha, J. H., Altabef, A. B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.033 · Cited by 394 · see citing works

Tumor immune evasion arises through loss of TNF sensitivity

Kearney, C. J., Vervoort, S. J., Hogg, S. J., Ramsbottom, K. M., Freeman, A. J., Lalaoui, N., Pijpers, L., Michie, J., Brown, K. K., Knight, D. A., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aar3451 · Cited by 381 · see citing works

Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells

Wang, X., Yang, L., Huang, F., Zhang, Q., Liu, S., Ma, L., & You, Z. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.02.006 · Cited by 327 · see citing works

Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia

Wang, X., Li, J., Dong, K., Fang, L., Long, M., Ouyang, Y., Wei, J., Chen, X., Weng, Y., He, T., et al. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.12.003 · Cited by 313 · see citing works

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

Hogg, S. J., Vervoort, S. J., Deswal, S., Ott, C. J., Li, J., Cluse, L. A., Beavis, P. A., Darcy, P. K., Martin, B. P., Spencer, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.011 · Cited by 308 · see citing works

Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer

Concha‐Benavente, F., Srivastava, R. M., Trivedi, S., Lei, Y. L., Chandran, U. R., Seethala, R. R., Freeman, G. J., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2001 · Cited by 306 · see citing works

A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples

Chen, H., Li, C., Peng, X., Zhou, Z., Weinstein, J. N., Johnson, R., Demchok, J. A., Felau, I., Kasapi, M., Ferguson, M. L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.027 · Cited by 298 · see citing works

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

Ellis, L., Pan, Y., Smyth, G. K., George, D. J., McCormack, C. J., Williams-Truax, R., Mita, M. M., Beck, J., Burris, H. A., Ryan, G. F., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4262 · Cited by 296 · see citing works

miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint

Xu, S., Tao, Z., Hai, B., Liang, H., Shi, Y. Q., Wang, T., Song, W., Chen, Y., Ouyang, J., Chen, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11406 · Cited by 290 · see citing works

The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion

Lu, C., Paschall, A. V., Shi, H., Savage, N. M., Waller, J. L., Sabbatini, M. E., Oberlies, N. H., Pearce, C. J., & Liu, K. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw283 · Cited by 264 · see citing works

MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer

Maeda, T., Hiraki, M., Jin, C., Rajabi, H. N., Tagde, A., Alam, M., Bouillez, A., Hu, X., Suzuki, Y., Miyo, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1636 · Cited by 251 · see citing works

PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer

Kansy, B., Concha‐Benavente, F., Srivastava, R. M., Jie, H.-B., Shayan, G., Lei, Y. L., Moskovitz, J. M., Moy, J. D., Li, J., Brandau, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3167 · Cited by 250 · see citing works

MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN-γ-Induced B7-H1 Expression in Cholangiocytes

Gong, A., Zhou, R., Hu, G., Li, X., Splinter, P. L., O’Hara, S. P., LaRusso, N. F., Soukup, G. A., Dong, H., & Chen, X. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1325 · Cited by 216 · see citing works

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma

Atsaves, V., Tsesmetzis, N., Chioureas, D., Kis, L. L., Leventaki, V., Drakos, E., Panaretakis, T., Grandér, D., Medeiros, L. J., Young, K. H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.103 · Cited by 184 · see citing works

PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non–Small Cell Lung Cancer

Ikeda, S., Okamoto, T., Okano, S., Umemoto, Y., Tagawa, T., Morodomi, Y., Kohno, M., Shimamatsu, S., Kitahara, H., Suzuki, Y., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.010 · Cited by 179 · see citing works

PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma

Ruf, M., Moch, H., & Schraml, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.30077 · Cited by 179 · see citing works

Essential role of HDAC6 in the regulation of PD‐L1 in melanoma

Lienlaf, M., Perez-Villarroel, P., Knox, T. J., Pabon, M. M., Sahakian, E., Powers, J. J., Woan, K. V., Lee, C., Cheng, F., Deng, S., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.012 · Cited by 171 · see citing works

RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers

Sumimoto, H., Takano, A., Teramoto, K., & Daigo, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166626 · Cited by 165 · see citing works

Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1

Maher, C. M., Thomas, J. D., Haas, D. A., Longen, C. G., Oyer, H. M., Tong, J. Y., & Kim, F. J. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0166 · Cited by 165 · see citing works

CD274/PD-L1gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity

Straub, M., Drecoll, E., Pfarr, N., Weichert, W., Langer, R., Hapfelmeier, A., Götz, C., Wolff, K., Kolk, A., & Specht, K. (2016) · Oncotarget · doi:10.18632/oncotarget.7593 · Cited by 162 · see citing works

IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma

Moon, J. W., Kong, S.-K., Kim, B. S., Kim, H. J., Lim, H., Noh, K., Kim, Y., Choi, J.-W., Lee, J.-H., & Kim, Y.-S. (2017) · Scientific Reports · doi:10.1038/s41598-017-18132-0 · Cited by 162 · see citing works

miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity

Jia, L., Xi, Q., Wang, H., Zhang, Z., Liu, H., Cheng, Y., Guo, X., Zhang, J., Zhang, Q., Zhang, L., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.074 · Cited by 159 · see citing works

EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3

Koh, J., Jang, J.-Y., Keam, B., Kim, S., Kim, M., Go, H., Kim, T. M., Kim, D., Kim, C. W., Jeon, Y. K., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1108514 · Cited by 153 · see citing works

PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer

Okita, R., Maeda, A., Shimizu, K., Nojima, Y., Saisho, S., & Nakata, M. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1986-y · Cited by 150 · see citing works

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma

Kao, S., Cheng, Y. Y., Williams, M., Kirschner, M. B., Madore, J., Lum, T., Sarun, K. H., Linton, A., McCaughan, B. C., Klebe, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.024 · Cited by 149 · see citing works

IL-27 induces the expression of IDO and PD-L1 in human cancer cells

Carbotti, G., Barisione, G., Airoldi, I., Mezzanzanica, D., Bagnoli, M., Ferrero, S., Petretto, A., Fabbi, M., & Ferrini, S. (2015) · Oncotarget · doi:10.18632/oncotarget.6530 · Cited by 147 · see citing works

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint

Wang, Q., Lin, W., Tang, X., Li, S., Guo, L., Lin, Y., & Kwok, H. F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122540 · Cited by 138 · see citing works

An intact immune system is required for the anticancer activities of histone deacetylase inhibitors

West, A. C., Mattarollo, S. R., Shortt, J., Cluse, L. A., Christiansen, A. J., Smyth, M. J., & Johnstone, R. W. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0890 · Cited by 137 · see citing works

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

Powles, T. B., Lackner, M. R., Oudard, S. M., Escudier, B. J., Ralph, C., Brown, J. E., Hawkins, R. E., Castellano, D., Rini, B. I., Staehler, M. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8808 · Cited by 135 · see citing works

PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p

Audrito, V., Serra, S., Stingi, A., Orso, F., Gaudino, F., Bologna, C., Neri, F., Garaffo, G., Nassini, R., Baroni, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15213 · Cited by 115 · see citing works

Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer

George, J., Saito, M., Tsuta, K., Iwakawa, R., Shiraishi, K., Scheel, A. H., Uchida, S., WATANABE, S.-I. I., Nishikawa, R., Noguchi, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1069 · Cited by 109 · see citing works

TLR4 Signaling Induces B7-H1 Expression Through MAPK Pathways in Bladder Cancer Cells

Qian, Y., Deng, J., Geng, L., Xie, H., Jiang, G., Zhou, L., Wang, Y., Yin, S., Feng, X., Liu, J., et al. (2008) · Cancer Investigation · doi:10.1080/07357900801941852 · Cited by 101 · see citing works

Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines

Yang, L., Huang, F., Mei, J., Wang, X., Zhang, Q., Wang, H., Xi, M., & You, Z. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000875 · Cited by 92 · see citing works

The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1

Cioffi, M., Trabulo, S. M. D., Vallespinós, M., Raj, D., Kheir, T. B., Lin, M.-L., Begum, J., Baker, A., Amgheib, A., Saif, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15450 · Cited by 88 · see citing works

NF-κB Plays a Key Role in Inducing CD274 Expression in Human Monocytes after Lipopolysaccharide Treatment

Huang, G., Wen, Q., Zhao, Y., Gao, Q., & Bai, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061602 · Cited by 86 · see citing works

Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells

Li, N., Wang, J., Zhang, N., Zhuang, M., Zong, Z., Zou, J., Li, G., Wang, X., Zhou, H., Zhang, L., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2086-8 · Cited by 79 · see citing works

TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells

Boes, M. L., & Meyer‐Wentrup, F. A. G. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.027 · Cited by 76 · see citing works

Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation

Quandt, D., Jasinski‐Bergner, S., Müller, U., Schulze, B., & Seliger, B. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-151 · Cited by 68 · see citing works

MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma

Wang, Y., Wang, D., Xie, G., Yin, Y., Zhao, E., Tao, K., & Li, R. (2017) · Oncotarget · doi:10.18632/oncotarget.15924 · Cited by 64 · see citing works

Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease

Diem, S., Ali, O. H., Ackermann, C. J., Bomze, D., Koelzer, V. H., Jochum, W., Speiser, D. E., Mertz, K. D., & Flatz, L. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2061-4 · Cited by 45 · see citing works

B7-H1, Which Represses EBV-Immortalized B Cell Killing by Autologous T and NK Cells, Is Oppositely Regulated by c-Myc and EBV Latency III Program at Both mRNA and Secretory Lysosome Levels

Durand-Panteix, S., Farhat, M., Youlyouz‐Marfak, I., Rouaud, P., Ouk, C., David, A., Faumont, N., Feuillard, J., & Jayat‐Vignoles, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102277 · Cited by 38 · see citing works

Induced B7-H1 expression on human renal tubular epithelial cells by the sublytic terminal complement complex C5b-9

Chen, Y., Zhang, J., Guo, G., Ruan, Z., Jiang, M., Wu, S., Guo, S. J., Fei, L., Tang, Y., Yang, C., et al. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.10.026 · Cited by 24 · see citing works

The current state of the art and future trends in RAS-targeted cancer therapies

Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549 · see citing works

M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling

Zong, Z., Zou, J., Mao, R., Ma, C., Li, N., Wang, J., Wang, X., Zhou, H., Zhang, L., & Shi, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01643 · Cited by 196 · see citing works

Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications

Himes, B. T., Geiger, P. A., Ayasoufi, K., Bhargav, A. G., Brown, D. A., & Parney, I. F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.770561 · Cited by 170 · see citing works

Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy.

Ju, X., Zhang, H., Zhou, Z., & Wang, Q. (2020) · PubMed Central · Cited by 108 · see citing works

Autoimmune endocrine dysfunctions associated with cancer immunotherapies

Ferrari, S. M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M. R., Baldini, E., Ulisse, S., Marone, G., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102560 · Cited by 107 · see citing works

Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review

Sławiński, G., Wrona, A., Dąbrowska-Kugacka, A., Raczak, G., & Lewicka, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197195 · Cited by 74 · see citing works

MRTF-A-NF-κB/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF-β

Du, F., Qi, X., Zhang, A., Sui, F., Wang, X., Proud, C. G., Lin, C., Fan, X., & Li, J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00670-3 · Cited by 74 · see citing works

Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy

Zhou, Y., Yuan, J. T., Xu, K., Li, S., & Liu, Y. (2024) · ACS Nano · doi:10.1021/acsnano.3c11260 · Cited by 73 · see citing works

Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC)

Bergmann, S., Coym, A., Ott, L. F., Soave, A., Rink, M., Janning, M., Stoupiec, M., Coith, C., Peine, S., Amsberg, G. V., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1738798 · Cited by 68 · see citing works

Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs

Wang, Q., Cao, Y., Shen, L., Xiao, T., Cao, R., Wei, S., Tang, M., Du, L., Wu, H., Wu, B., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq4722 · Cited by 66 · see citing works

The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?

Lamberti, G., Sisi, M., Andrini, E., Palladini, A., Giunchi, F., Lollini, P., Ardizzoni, A., & Gelsomino, F. (2020) · Cancers · doi:10.3390/cancers12113129 · Cited by 64 · see citing works

Local Targeting of NAD+ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma

Li, M., Kirtane, A. R., Kiyokawa, J., Nagashima, H., Lopes, A., Tirmizi, Z. A., Lee, C. K., Traverso, G., Cahill, D. P., & Wakimoto, H. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1094 · Cited by 59 · see citing works

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges

Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 57 · see citing works

PD-L1/PD-1 axis as a potent therapeutic target in breast cancer

Bastaki, S., Irandoust, M., Ahmadi, A., Hojjat‐Farsangi, M., Ambrose, P., Hallaj, S., Edalati, M., Ghalamfarsa, G., Azizi, G., Yousefi, M., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117437 · Cited by 50 · see citing works

Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy

Ayala‐Mar, S., Donoso‐Quezada, J., & González‐Valdez, J. (2021) · Journal of Immunology Research · doi:10.1155/2021/8839978 · Cited by 50 · see citing works

Going to extremes: determinants of extraordinary response and survival in patients with cancer

Saner, F. A. M., Herschtal, A., Nelson, B. H., DeFazio, A., Goode, E. L., Ramus, S. J., Pandey, A., Beach, J. A., Fereday, S., Berchuck, A., et al. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0145-5 · Cited by 51 · see citing works

EGFR‐ERK pathway regulates CSN6 to contribute to PD‐L1 expression in glioblastoma

Su, L., Guo, W., Lou, L., Nie, S., Zhang, Q. H., Liu, Y., Chang, Y., Zhang, X., Li, Y., & Shen, H. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23176 · Cited by 50 · see citing works

IL1R2 Blockade Alleviates Immunosuppression and Potentiates Anti-PD-1 Efficacy in Triple-Negative Breast Cancer

Xia, J., Zhang, L., Peng, X., Tu, J., Li, S., He, X., Li, F., Qiang, J., Dong, H., Deng, Q., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3429 · Cited by 49 · see citing works

Propranolol reduces IFN-γ driven PD-L1 immunosuppression and improves anti-tumour immunity in ovarian cancer

Falcinelli, M., Alhity, G., Baron, S., Mampay, M., Allen, M. C., Samuels, M. E., Jones, W., Cilibrasi, C., Flaherty, R. L., Giamas, G., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.02.011 · Cited by 43 · see citing works

The dual roles of A20 in cancer

Shi, Y., Wang, X., Wang, J., Wang, X., Zhou, H., & Zhang, L. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.017 · Cited by 44 · see citing works

Upregulated glycolysis correlates with tumor progression and immune evasion in head and neck squamous cell carcinoma

Takahashi, H., Kawabata‐Iwakawa, R., Ida, S., Mito, I., Tada, H., & Chikamatsu, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-97292-6 · Cited by 43 · see citing works

Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma

Takahashi, H., Sakakura, K., Arisaka, Y., Tokue, A., Kaira, K., Tada, H., Higuchi, T., Okamoto, A., Tsushima, Y., & Chikamatsu, K. (2019) · Anticancer Research · doi:10.21873/anticanres.13437 · Cited by 40 · see citing works

Modulation of the PD-1/PD-L1 immune checkpoint axis during inflammation-associated lung tumorigenesis

Narayanapillai, S. C., Han, Y. H., Song, J. M., Kebede, M. E., Upadhyaya, P., & Kassie, F. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa059 · Cited by 38 · see citing works

Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis

Wang, S., Yuan, B., Wang, Y., Li, M., Liu, X., Cao, J., Li, C., & Hu, J. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03734-4 · Cited by 36 · see citing works

Old and New Players of Inflammation and Their Relationship With Cancer Development

Chavez-Dominguez, R., Perez-Medina, M., Aguilar‐Cázares, D., Galicia-Velasco, M., Meneses-Flores, M., Islas-Vázquez, L., Camarena, Á., & López-González, J. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722999 · Cited by 39 · see citing works

Nuclear PD-L1 promotes cell cycle progression of BRAF-mutated colorectal cancer by inhibiting THRAP3

Ma, R., Liu, Y., Che, X., Li, C., Wen, T., Hou, K., & Qu, X. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.017 · Cited by 36 · see citing works

Local Targeting of NAD+ Salvage Pathway Alters the Immune Tumor Microenvironment and Enhances Checkpoint Immunotherapy in Glioblastoma

Li, M., Kirtane, A. R., Kiyokawa, J., Nagashima, H., Lopes, A., Tirmizi, Z. A., Lee, C. K., Traverso, G., Cahill, D. P., & Wakimoto, H. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0525 · Cited by 35 · see citing works

The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges

Stege, H. M., Haist, M., Nikfarjam, U., Schultheis, M., Heinz, J., Pemler, S., Loquai, C., & Grabbe, S. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00840-3 · Cited by 35 · see citing works

Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond

Aden, D., Zaheer, S., Sureka, N., Trisal, M., Chaurasia, J. K., & Zaheer, S. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155864 · Cited by 37 · see citing works

Prognostic Impact of Adenosine Receptor 2 (A2aR) and Programmed Cell Death Ligand 1 (PD-L1) Expression in Colorectal Cancer

Wu, Z., Yang, L., Shi, L., Hu, S., Shi, P.-C., Yang, T., Fan, R., Jiang, T., & Song, J. (2019) · BioMed Research International · doi:10.1155/2019/8014627 · Cited by 34 · see citing works

Molecular profiling of circulating tumor cells predicts clinical outcome in head and neck squamous cell carcinoma

Tada, H., Takahashi, H., Kuwabara-Yokobori, Y., Shino, M., & Chikamatsu, K. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104558 · Cited by 33 · see citing works

Superinduction of immunosuppressive glioblastoma extracellular vesicles by IFN-γ through PD-L1 and IDO1

Jung, M. K., Aibaidula, A., Brown, D. A., Himes, B. T., Garcia, L. M. C., & Parney, I. F. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac017 · Cited by 32 · see citing works

PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung

Goldmann, T., Marwitz, S., Nitschkowski, D., Krupar, R., Backman, M., Elfving, H., Thurfjell, V., Lindberg, A., Brunnström, H., Fleur, L. L., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02825-z · Cited by 31 · see citing works

γδ T cells in hepatocellular carcinoma patients present cytotoxic activity but are reduced in potency due to IL-2 and IL-21 pathways

Jiang, H., Zhao, Y., Song, Z., Green, M., Song, H., & Shao, Q. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.02.019 · Cited by 30 · see citing works

Impact of inflammation and immunotherapy in renal cell carcinoma (Review)

Shi, J., Wang, K., Xiong, Z., Yuan, C., Wang, C., Cao, Q., Huang, Y., Meng, X., Xie, K., Cheng, Z., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.12135 · Cited by 28 · see citing works

Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates

Shi, Y., Fan, G., Tan, R., Li, S., Sun, H., Li, R., Yang, M., Gao, S., Liu, M., & Dai, M.-Y. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07073-y · Cited by 27 · see citing works

Ubiquitin C‐terminal hydrolase L1 promotes expression of programmed cell death‐ligand 1 in non‐small‐cell lung cancer cells

Mao, R., Tan, X., Xiao, Y., Wang, X., Wei, Z., Wang, J., Wang, X., Zhou, H., Zhang, L., & Shi, Y. (2020) · Cancer Science · doi:10.1111/cas.14529 · Cited by 26 · see citing works

The PKC universe keeps expanding: From cancer initiation to metastasis

Rahimova, N., Cooke, M., Zhang, S., Baker, M. J., & Kazanietz, M. G. (2020) · Advances in Biological Regulation · doi:10.1016/j.jbior.2020.100755 · Cited by 26 · see citing works

The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective

Liang, S., Wang, H., Tian, H., Xu, Z., Wu, M., Hua, D., & Li, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1249980 · Cited by 25 · see citing works

Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy

Cuyàs, E., Verdura, S., Martı́n-Castillo, B., Alarcón, T., Lupu, R., Bosch‐Barrera, J., & Menéndez, J. A. (2020) · Cancers · doi:10.3390/cancers12071757 · Cited by 25 · see citing works

A Novel Bispecific Antibody with PD-L1–assisted OX40 Activation for Cancer Treatment

Kuang, Z., Pu, P., Wu, M. H., Wu, Z., Wang, L., Li, Y., Zhang, S., Hua, J., Wu, W., Chen, B., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0226 · Cited by 25 · see citing works

Boosting Anti-tumour Immunity Using Adjuvant Apigenin

Xiao, C., Najafi, M., Huang, J., Chen, X., & Chang, Z. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220523151409 · Cited by 25 · see citing works

RNA-biology ruling cancer progression? Focus on 3′UTRs and splicing

Erson-Bensan, A. E. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09884-9 · Cited by 23 · see citing works

Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma

Lorenzo-Sanz, L., Lopez-Cerda, M., da Silva-Diz, V., Artés, M. H., Llop, S., Penín, R., Bermejo, J., González-Suárez, E., Esteller, M., Viñals, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49718-8 · Cited by 22 · see citing works

PD-1/PD-L1 Blockade Accelerates the Progression of Atherosclerosis in Cancer Patients

Dong, M., Yu, T., Tse, G., Lin, Z., Lin, C., Zhang, N., Wang, R., Liu, T., & Zhong, L. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101527 · Cited by 19 · see citing works

A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets

Cai, Z., Ang, X., Xu, Z., Li, S., Zhang, J., Pei, C.-S., & Zhou, F. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-561 · Cited by 18 · see citing works

Downregulation of Interferon-γ Receptor Expression Endows Resistance to Anti–Programmed Death Protein 1 Therapy in Colorectal Cancer

Lv, C., Yuan, D., & Cao, Y. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000284 · Cited by 17 · see citing works

Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression

Sudoyo, A. W., Kurniawan, A. N., Kusumo, G. D., Putra, T. P., Rexana, F., Yunus, M., Budiyati, A. D., Kurniawan, D., Utama, A., & Utomo, A. R. H. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.11.3421 · Cited by 17 · see citing works

IQGAP1 is positively correlated with PD-L1 and regulates its expression via mediating STAT proteins phosphorylation

Chen, Y., Mei, J., Zhang, P., Liu, J., Chen, L., Wu, L., & Zhang, Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108897 · Cited by 14 · see citing works

Protein Kinase C Alpha is a Central Node for Tumorigenic Transcriptional Networks in Human Prostate Cancer

Cooke, M., Zhang, X., Zhang, S., Eruslanov, E. B., Lal, P., Daniel, R. E., Feldman, M. D., Abba, M. C., & Kazanietz, M. G. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0170 · Cited by 13 · see citing works

Predictive Markers of Immune Response in Glioblastoma: Hopes and Facts

Nunno, V. D., Franceschi, E., Gatto, L., Bartolini, S., & Brandes, A. A. (2020) · Future Oncology · doi:10.2217/fon-2020-0047 · Cited by 13 · see citing works

Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target

Koni, M., Castellano, I., Venturelli, E., Sarcinella, A., Lopatina, T., Grange, C., Cedrino, M., Femminò, S., Cossu‐Rocca, P., Orrù, S., et al. (2022) · Cancers · doi:10.3390/cancers14163918 · Cited by 13 · see citing works

Natural Killer and T Cell Infiltration in Canine Osteosarcoma: Clinical Implications and Translational Relevance

Razmara, A. M., Judge, S. J., Gingrich, A. A., Cruz, S. M., Culp, W. T. N., Kent, M. S., Rebhun, R. B., & Canter, R. J. (2021) · Frontiers in Veterinary Science · doi:10.3389/fvets.2021.771737 · Cited by 12 · see citing works

FGFR inhibitors promote the autophagic degradation of IFN-γ-induced PD-L1 and alleviate the PD-L1-mediated transcriptional suppression of FGFR3-TACC3 in non-muscle-invasive bladder cancer

Lin, Y.-C., Chu, C., Hsieh, T., Lin, B.-J., Liou, J., Yen, Y., & Chen, C. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07821-8 · Cited by 10 · see citing works

The role of tumor microenvironment and signaling pathways in regulating breast cancer stem cells: Implications for therapy resistance and tumor recurrence

Zhang, H., Sun, Y., Liu, R., Hamdy, H., Shi, Z., Jiang, D., & Sun, J. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101315 · Cited by 10 · see citing works

Genes Involved in the PD-L1 Pathway Might Associate with Radiosensitivity of Patients with Gastric Cancer

Du, Z., Yan, D., Li, Z., Gu, J., Tian, Y., Cao, J., & Tang, Z. (2020) · Journal of Oncology · doi:10.1155/2020/7314195 · Cited by 9 · see citing works

RAD51Bme Levels as a Potential Predictive Biomarker for PD-1 Blockade Response in Non-Small Cell Lung Cancer

Guerreiro, I. M., Barros‐Silva, D., Lopes, P., Cantante, M., Cunha, A. L., Lobo, J., Antunes, L., Rodrigues, A., Soares, M., Henrique, R., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041000 · Cited by 9 · see citing works

In silico screening and surface plasma resonance‐based verification of programmed death 1‐targeted peptides

Zhang, P., Li, C., Ji, X., Gao, M., Lyu, S., Dai, X., & Du, J. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13647 · Cited by 7 · see citing works

Efficacy of PD-1 or PD-L1 inhibitors for the therapy of cervical cancer with varying PD-L1 expression levels: a single-arm meta-analysis

Yang, J., Yu, H., Zhang, Y., Zhu, M., Zhang, M., & Wang, Q. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1454372 · Cited by 6 · see citing works

Analysis of Th1/Th2 cytokine profile and clinical characteristics of patients with head and neck squamous cell carcinoma

Wang, R., Yin, G., Guo, W., Li, N., Zhang, Y., Chen, X., & Huang, Z. (2024) · Biomolecules and Biomedicine · doi:10.17305/bb.2024.10783 · Cited by 5 · see citing works

Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy

Таширева, Л. А., Muravyova, D. T., Popova, N. O., Goldberg, V. E., Vtorushin, S. V., & Михайлович, П. В. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921110092 · Cited by 5 · see citing works

Genomic Stratification Based on Radiosensitivity and PD-L1 for Tailoring Therapeutic Strategies in Cervical Cancer

Lyu, X., Jiang, Y., Zhang, M., Li, G., Li, G., & Qiao, Q. (2019) · Epigenomics · doi:10.2217/epi-2019-0108 · Cited by 5 · see citing works

The shifting paradigm of programmed cell death ligand 1 (PD-L1) in anaplastic thyroid carcinoma: from pathology to clinical practice

Fiorentino, V., Ballato, M., Pepe, L. R., Zuccalà, V., Pizzimenti, C., Cianci, V., Mondello, C., Cannavò, S., Campennì, A., Tralongo, P., et al. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04354-5 · Cited by 4 · see citing works

Using 18F-FDG PET/CT to predict programmed cell death ligand expression in non-small cell lung cancer via metabolic tumour heterogeneity

Chang, R., Luo, L., Shen, C., Zhang, W., & Duan, X. (2025) · British Journal of Radiology · doi:10.1093/bjr/tqaf034 · Cited by 4 · see citing works

Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?

Sun, D., An, L., Huang, H., Sun, X., & Lv, G.-Y. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02390-y · Cited by 4 · see citing works

Recent advances in peptide-drug conjugates as anticancer agents

Feng, Y., Li, T., Li, S., Liu, Z., Tang, Z., Chen, C., Zhou, C., Lu, T., & Chen, J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118482 · Cited by 3 · see citing works

Structural Exploration on Palmitoyltransferase DHHC3 from Homo sapiens

Tang, M., Xia, Y., Xiao, T., Cao, R., Cao, Y., & OuYang, B. (2022) · Polymers · doi:10.3390/polym14153013 · Cited by 3 · see citing works

MDA-MB-231 breast cancer cells adapted to anchorage-independent growth reveal senescent-like phenotype and persistent downregulation of PD-L1 expression

Snedec, T., Repas, J., Lah, D., Jokhadar, Š. Z., & Pavlin, M. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1667308 · Cited by 2 · see citing works

Unraveling Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities: Pathway Insights, Mechanisms, and Emerging Therapeutic Targets

Zhang, B., Muhetarijiang, M., Sun, X., Wu, Y., Justin, R., Li, Z., Chen, T., Zhou, D., & Hu, X. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm43846 · Cited by 2 · see citing works

Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer

Bae, S. U., Lee, H. W., Park, J. Y., Seo, I., Cho, J.-M., Kim, J. Y., Lee, J. Y., Lee, Y. J., Baek, S. K., Kim, N. K., et al. (2024) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2024.100906 · Cited by 2 · see citing works

Explore association of genes in PDL1/PD1 pathway to radiotherapy survival benefit based on interaction model strategy

Shen, J., Liu, J., Li, H., Bai, L., Du, Z., Geng, R., Cao, J., Sun, P., & Tang, Z. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01951-x · Cited by 2 · see citing works

Expression of Programmed Death Ligand 1 (PD-L1) in Breast Cancer patients in India and its Correlation with Prognostic Parameters

Punhanni, P., & Ahluwalia, C. (2023) · Archives of Breast Cancer · doi:10.32768/abc.2023103280-290 · Cited by 2 · see citing works

Development and Characterization of an Anti-PD-L1 Immunotoxin for Targeted Cancer Therapy

Takhteh, A., Hosseininejad-Chafi, M., Oghalaie, A., Behdani, M., & Kazemi‐Lomedasht, F. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010321088240823062243 · Cited by 1 · see citing works

ANP32A negatively regulates PD-L1 expression by acting as the inhibitor of histone acetylase in non-small cell lung cancer

Li, J., Hao, J., Huang, D., Lu, D., Wu, L., Zhou, X., Liu, Y., Long, Y., Wang, L., Hu, H., et al. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102177 · Cited by 1 · see citing works

Immune checkpoint inhibitors in medulloblastoma: current updates in preclinical and clinical developments

Welch, R. L., Moziak, K., Zang, X., & Martin, A. L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1725230 · Cited by 1 · see citing works

Macrophage Polarization as a Target for Colorectal Cancer Treatment Optimization: A Systematic Review

Seraphine, C., MacLeod, A., Thornsberry, T., Dharmadhikari, S., Martinez, B., Gable, C., Chambers, A., Jaganathan, V. L., Littlefield, A., & Galandiuk, S. (2026) · Cancers · doi:10.3390/cancers18132049 · Cited by 1 · see citing works

PD-1 Signaling in Extramammary Paget Disease

Dany, M. (2020) · Cutis · doi:10.12788/cutis.0023 · Cited by 1 · see citing works

PD-L1 and CD8+ T cell evaluation in breast cancers and their correlation with clinicopathological parameters

Kazmi, S., Shawana, S., & Jamal, N. (2024) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.10567 · Cited by 1 · see citing works

Evaluation of programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1) as tumor biomarkers an in patients with head and neck squamous cell carcinoma

Deliverska, E., Forghani, P., & Parusheva, S. (2020) · Journal of Medical and Dental Practice · doi:10.18044/medinform.202072.1198 · Cited by 1 · see citing works

Mechanisms of PD-L1 Regulation in Tumor Immune Ecosystem

Bangash, F., Alia, S., & Gul, R. (2022) · Journal of Biomedical Research & Environmental Sciences · doi:10.37871/jbres1525 · Cited by 1 · see citing works

ROLE OF PD-L1 ASSESSMENT IN THE ASPECT OF MOLECULAR-GENETIC CLASSIFICATION OF COLORECTAL CANCER. CURRENT STATE OF THE PROBLEM

Vtorushin, S. V., Naumov, S. S., Stepanov, I. V., Sinyanskiy, L. E., & Afanasyev, S. G. (2021) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2021-20-1-115-122

Exploration to Identify Radiosensitive Genes in PD-L1 Expression and PD-1 check Point Pathway in CancerPreprint

Shen, J., Liu, J., Li, H., Bai, L., Geng, R., Cao, J., Sun, P., & Tang, Z. (2021) · Research Square · doi:10.21203/rs.3.rs-501265/v1

Integrate Exploration to Identify Radiosensitive Biomarkers in Genes in PD-L1 Expression and PD-1 Check Point Pathway in CancerPreprint

Shen, J., Liu, J., Li, H., Bai, L., Geng, R., Cao, J., Sun, P., & Tang, Z. (2021) · Research Square · doi:10.21203/rs.3.rs-433504/v1

Upregulated Glycolysis Correlates With Clinical and Transcriptomic Significances in Head and Neck Squamous Cell CarcinomaPreprint

Takahashi, H., Kawabata‐Iwakawa, R., Ida, S., Mito, I., Tada, H., & Chikamatsu, K. (2021) · Research Square · doi:10.21203/rs.3.rs-421251/v1

Параметры микроокружения опухоли определяют эффективность анти-PD-1/PD-L1-терапии

Таширева, Л. А., Muravyova, D. T., Popova, N. O., Goldberg, V. E., Vtorushin, S. V., & Михайлович, П. В. (2021) · Biochemistry (Moscow) · doi:10.31857/s0320972521110063

Data from A Novel Bispecific Antibody with PD-L1–assisted OX40 Activation for Cancer Treatment

Kuang, Z., Pu, P., Wu, M., Wu, Z., Wang, L., Li, Y., Zhang, S., Hua, J., Wu, W., Chen, B., et al. (2023) · doi:10.1158/1535-7163.c.6542038.v1

Data from A Novel Bispecific Antibody with PD-L1–assisted OX40 Activation for Cancer Treatment

Kuang, Z., Pu, P., Wu, M., Wu, Z., Wang, L., Li, Y., Zhang, S., Hua, J., Wu, W., Chen, B., et al. (2023) · doi:10.1158/1535-7163.c.6542038

Investigating the correlation between PD-L1 expression and radiomics predictions in non-small cell lung cancer using PET/CT imaging analysisPreprint

Chang, R., Shen, C., Luo, L., Liu, X., Li, Y., & Duan, X. (2024) · Research Square · doi:10.21203/rs.3.rs-4207471/v1

Expression of PD-L1 (DAKO 28-8) in Urothelial Carcinoma of Urinary Bladder

Azmat, H., Masood, A., Chaudry, S. S., Mushir, S. I., Sheikh, A. K., & Riaz, S. K. (2024) · Asian Pacific Journal of Cancer Biology · doi:10.31557/apjcb.2024.9.2.179-182

Evaluation of cd44 and Pd-L1 expression during co-cultivation of tumor and hematopoietic stem cells

Bykova, M. V., Aktanova, A. A., Skachkov, I. P., Denisova, V. V., & Pashkina, E. A. (2025) · Oncohematology · doi:10.17650/1818-8346-2025-20-1-122-127

Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with PD-L1 amplification: a case report

Kodama, H., Masuishi, T., Ishizuka, Y., Sakakida, T., Honda, K., Narita, Y., Taniguchi, H., Kadowaki, S., Ando, M., Hosoda, W., et al. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261451859

CAPZ regulates endosomal–exosomal trafficking of plasma membrane PD-L1 independently of canonical autophagy

Xu, P., Ye, Z., Zhu, Y., Chan, C.-F., Li, Y., Huang, H., Zhu, C., Zhang, X., Wang, Y., Wang, Y., et al. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113612

Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy.

Ju, X., Zhang, H., Zhou, Z., & Wang, Q. (2020) · PubMed Central · Cited by 108 · see citing works

The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells

Lin, Q., Wang, X., & Hu, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216318 · Cited by 78 · see citing works

PD-L1: expression regulation

Zhou, Y.-J., Li, G., Wang, J., Liu, M., Wang, Z., Song, Y., Zhang, X., & Wang, X. (2023) · Blood Science · doi:10.1097/bs9.0000000000000149 · Cited by 85 · see citing works

Regulation of PD-L1 expression in the tumor microenvironment

Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681 · see citing works

Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms to clinical applications

Zhang, Y., Yin, K., Ma, R., Sun, Y., Wang, L., & Yin, D. (2025) · iScience · doi:10.1016/j.isci.2025.112615 · Cited by 7 · see citing works